Analytical Data
-
Gene name
KRAS
- Application
-
Alternative Names
KRAS;KRAS2;RASK2;GTPase KRas
-
Species
Human
-
Source
HEK293
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P01116
-
Expression Region
2-185aa
-
Molecular Weight
22.5 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Identification
Protein Description
KRAS is a prominent oncogene that plays a crucial role in cell signaling pathways regulating cell growth and differentiation. Mutations in KRAS are frequently associated with various cancers, including pancreatic, colorectal, and lung cancers, making it a significant target for cancer research and therapy. The KRAS protein acts as a molecular switch, cycling between an active GTP-bound state and an inactive GDP-bound state, thus influencing downstream signaling pathways like the MAPK and PI3K-Akt pathways. Understanding the structure and function of recombinant KRAS proteins is vital for elucidating the mechanisms of oncogenesis and for the development of targeted therapies. Recent advances in molecular biology techniques have allowed for the successful expression and purification of recombinant KRAS proteins, enabling researchers to study their biochemical properties, interactions with other cellular components, and the effects of specific mutations. Furthermore, the development of specific inhibitors targeting mutant KRAS variants, such as KRASG12C, has shown promise in clinical settings, underscoring the importance of continuing research in this area. This knowledge not only enhances our understanding of cancer biology but also paves the way for novel therapeutic strategies aimed at disrupting the pathological signaling pathways activated by mutated KRAS, ultimately improving treatment outcomes for patients with KRAS-driven malignancies.
